LAS VEGAS—Direct-to-consumer health companies Noom and Hims & Hers are making a play for the booming peptide market as the federal government loosens restrictions on compounded treatments.
The companies are betting that peptides could be the next big thing in consumer health. For Noom, the new peptide offering extends the company's business beyond weight loss into the broader longevity and wellness market. Hims & Hers signaled months ago that it was ready to tap into the multi-billion-dollar peptide market.
Federal policy shifts and U.S. Food and Drug Administration enforcement discretion around compounded peptides have opened new pathways for telehealth and compounding pharmacies.
On Tuesday, Noom launched OpenRx as a separate peptide and preventive health brand. At launch, OpenRx offers two injectable options: sermorelin, a peptide frequently prescribed for muscle support, and NAD+, a coenzyme frequently prescribed for energy. OpenRx also offers two oral dissolvable tablet options: the first formulation combines the peptides PT-141 and oxytocin with tadalafil to support sexual health. The second ODT formulation is the peptide oxytocin to support intimacy.
Noom says it plans to expand into other areas including recovery, muscle health, skin, gut health and sleep. Peptides are small pieces of protein that occur naturally in the body and help control functions such as growth, healing and appetite.
“Peptides are an important portion of the formulary of healthy aging,” Geoff Cook, CEO of Noom, said in a statement. “OpenRx enables our flagship Noom brand to deepen into cardiometabolic health while the new brand OpenRx supports patients with conditions too often neglected by traditional care models, like energy, muscle composition, skin health, sexual health, sleep, and recovery.
Source link







